Article History
Received: 7 January 2020
Revised: 23 April 2020
Accepted: 19 June 2020
First Online: 7 July 2020
Compliance with ethical standards
:
: SJH was or is a member of the scientific advisory board of Rodin Therapeutics, Psy Therapeutics, Frequency Therapeutics, and Souvien Therapeutics, none of whom were involved in the present study. SJH has also received speaking or consulting fees from Amgen, AstraZeneca, Biogen, Merck, Regenacy Pharmaceuticals, Syros Pharmaceuticals, Juvenescence, as well as sponsored research or gift funding from AstraZeneca, JW Pharmaceuticals, and Vesigen unrelated to the content of this manuscript. RHP is a member of the scientific advisory board of Psy Therapeutics, Outermost Therapeutics, and Genomind, and reports consulting fees from Genomind, RID Ventures, Takeda, and Burrage Capital. He holds equity in Psy Therapeutics and Outermost Therapeutics. All of these are unrelated to the content of this manuscript. RK: None.